Willis Investment Counsel boosted its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 36.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 320,600 shares of the company's stock after purchasing an additional 84,900 shares during the quarter. Willis Investment Counsel's holdings in Sanofi were worth $17,780,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. McClarren Financial Advisors Inc. lifted its stake in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares during the period. Lee Danner & Bass Inc. bought a new position in Sanofi during the fourth quarter worth about $31,000. Bessemer Group Inc. lifted its stake in Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after purchasing an additional 242 shares during the period. Sierra Ocean LLC bought a new position in Sanofi during the fourth quarter worth about $44,000. Finally, UMB Bank n.a. lifted its stake in Sanofi by 30.7% during the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after purchasing an additional 264 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.
Sanofi Price Performance
NASDAQ:SNY traded down $1.16 during mid-day trading on Friday, reaching $49.67. 2,303,891 shares of the company were exchanged, compared to its average volume of 2,381,876. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12. The company has a fifty day moving average of $51.49 and a 200 day moving average of $52.03. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock has a market cap of $121.81 billion, a PE ratio of 19.95, a PEG ratio of 1.01 and a beta of 0.50.
Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. The company's revenue was down 11.0% on a year-over-year basis. On average, research analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.
Sanofi Increases Dividend
The business also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were issued a dividend of $2.0369 per share. The ex-dividend date was Friday, May 9th. This represents a yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio is currently 56.79%.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on SNY shares. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. The Goldman Sachs Group started coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. BNP Paribas started coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price on the stock. Finally, Morgan Stanley set a $56.00 target price on shares of Sanofi in a report on Monday, June 2nd. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $61.50.
View Our Latest Stock Analysis on Sanofi
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
